lifestyle.newsblaze.com

Author: Cue Biopharma, Inc.

Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026

April 15, 2026
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

April 8, 2026
Cue Biopharma Announces CEO Transition

March 27, 2026
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

March 26, 2026
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

March 16, 2026
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026

March 9, 2026
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases

February 17, 2026
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer

February 13, 2026